Anemia Control in Kidney Transplant Recipients Using Once-Monthly Continuous Erythropoietin Receptor Activator: A Prospective, Observational Study
In a multicenter, prospective, observational study of 279 kidney transplant recipients with anemia, the efficacy and safety of once-monthly continuous erythropoietin receptor activator (C.E.R.A.) were assessed to a maximum of 15 months. The main efficacy variable was the proportion of patients achie...
Main Authors: | Klemens Budde, Thomas Rath, Volker Kliem |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2014-01-01
|
Series: | Journal of Transplantation |
Online Access: | http://dx.doi.org/10.1155/2014/179705 |
Similar Items
-
A prospective study of daclatasvir and sofosbuvir in chronic HCV-infected kidney transplant recipients
by: Michael Duerr, et al.
Published: (2019-02-01) -
Improvement of medication adherence with simplified once-daily immunosuppressive regimen in stable kidney transplant recipients: A prospective cohort study
by: Chang-Kwon Oh, et al.
Published: (2020-06-01) -
Anaemia in kidney transplant recipients : effects of recombinant human erythropoietin and the potential role of mycophenolate mofetil
by: Pile, Taryn
Published: (2012) -
Transfusion-Dependent Anemia in a Simultaneous Pancreas and Kidney Transplant Recipient
by: Jeevan Prakash Gopal, et al.
Published: (2020-01-01) -
Posttransplant Anemia as a Prognostic Factor of Mortality in Kidney-Transplant Recipients
by: Maria Majernikova, et al.
Published: (2017-01-01)